Amendment to Seth Harmon Employment Agreement, dated September 28, 2023

THIS AMENDMENT (“Amendment”) is made as of September 28, 2023 by and between Viridian Therapeutics Inc., a Delaware corporation with a principal business address at 221 Crescent Street, Suite 401, Waltham, MA 02453 (the “Company”), and Seth Harmon, with an address at 74 Chebacco Road, Hamilton, MA 01982 (“Executive”).

WHEREAS, the Company and the Executive are parties to an Employment Agreement, effective as of April 24, 2023 (the “Agreement”) and the Company and Executive wish to amend the terms of the Agreement as set forth below, effective September 12, 2023.

NOW THEREFORE, it is hereby agreed as follows:

1.Section 5(a) of the Agreement shall be deleted in its entirety and replaced with the following:

(a) Base Salary. During Executive’s employment with the Company, the Company shall pay Executive a base salary at the annual rate of $410,000 USD less payroll deductions and withholdings, which shall be payable in accordance with the standard payroll practices of the Company, pursuant to which Executive will be compensated on a semi-monthly basis. The Executive’s base salary shall be subject to periodic review and adjustment by the Board from time to time in the discretion of the Board.

2.Section 8(b)(i) of the Agreement shall be deleted in its entirety and replaced with the following:

(b) Executive shall receive continued payment of Executive’s Base Salary (as defined below) for twelve (12) months after the date of such termination (the “Severance Period”), paid over the Company’s regular payroll schedule.

IN WITNESS WHEREOF, the parties have executed this Amendment as of the Effective Date.

By: /s/ Scott Myers                    By: /s/ Seth Harmon        

Scott Myers                                Seth Harmon

President and CEO

Date: Sep 28, 2023                    Date: Sep 28, 2023